Aratana Therapeutics, Inc.
PETX
PETX was delisted on the 17th of July, 2019.
96 hedge funds and large institutions have $194M invested in Aratana Therapeutics, Inc. in 2017 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 40 increasing their positions, 15 reducing their positions, and 14 closing their positions.
777% more call options, than puts
Call options by funds: $386K | Put options by funds: $44K
167% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 15
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
9% less funds holding
Funds holding: 105 → 96 (-9)
14% less capital invested
Capital invested by funds: $227M → $194M (-$32.4M)
57% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAI
General American Investors
New York
|
+$1.58M |
| 2 |
BlackRock
New York
|
+$750K |
| 3 |
DC
Davenport & Co
Richmond,
Virginia
|
+$671K |
| 4 |
Alyeska Investment Group
Chicago,
Illinois
|
+$581K |
| 5 |
Renaissance Technologies
New York
|
+$508K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.13M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.12M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$723K |
| 4 |
TCIM
TIAA CREF Investment Management
New York
|
-$567K |
| 5 |
3C
361 Capital
Denver,
Colorado
|
-$405K |
PETX Hedge Fund Activity: Q3 2017 in Review
96 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Aratana Therapeutics, Inc. (PETX) for Q3 2017, worth a combined $194M — down 14% from $227M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of PETX and 6 opened new positions — a net loss of 8 holders — while 15 trimmed existing stakes and 40 added.
The largest buyer was General American Investors, adding an estimated $1.58M. The largest seller was Acadian Asset Management, exiting entirely with an estimated $1.13M sold.
- 96 institutional investors held Aratana Therapeutics, Inc. (PETX) as of Q3 2017, down from 105 in Q2 2017.
- Funds reported $194M of Aratana Therapeutics, Inc. stock for Q3 2017, down 14% quarter-over-quarter.
- 6 funds opened new Aratana Therapeutics, Inc. positions in Q3 2017 and 14 closed out, a net change of -8 holders.
- The largest Aratana Therapeutics, Inc. buyer in Q3 2017 was General American Investors, an estimated $1.58M added.
- The largest Aratana Therapeutics, Inc. seller in Q3 2017 was Acadian Asset Management, an estimated $1.13M sold.
Based on aggregated 13F filings for Q3 2017.